Cabozantinib Shows Strong Activity in RAI-Refractory Thyroid Cancer

Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.

Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Thyroid Cancer Source Type: news